Search

Your search keyword '"Jiménez-Ríos, Miguel A."' showing total 15 results
Start Over Author "Jiménez-Ríos, Miguel A." Search Limiters Full Text
15 results on '"Jiménez-Ríos, Miguel A."'

2. CT Rendering and Radiomic Analysis in Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Testicular Cancer to Anticipate Difficulties for Young Surgeons

Author

Scavuzzo, Anna, primary, Figueroa-Rodriguez, Pavel, additional, Stefano, Alessandro, additional, Jimenez Guedulain, Nallely, additional, Muruato Araiza, Sebastian, additional, Cendejas Gomez, Jose de Jesus, additional, Quiroz Compeaán, Alejandro, additional, Victorio Vargas, Dimas O., additional, and Jiménez-Ríos, Miguel A., additional

Published
2023
Full Text
View/download PDF

3. Mutational Landscape of Bladder Cancer in Mexican Patients: KMT2D Mutations and chr11q15.5 Amplifications Are Associated with Muscle Invasion

Author

Pérez-Montiel, María D., primary, Cerrato-Izaguirre, Dennis, additional, Sánchez-Pérez, Yesennia, additional, Diaz-Chavez, Jose, additional, Cortés-González, Carlo César, additional, Rubio, Jairo A., additional, Jiménez-Ríos, Miguel A., additional, Herrera, Luis A., additional, Scavuzzo, Anna, additional, Meneses-García, Abelardo, additional, Hernández-Martínez, Ricardo, additional, Vaca-Paniagua, Felipe, additional, Ramírez, Andrea, additional, Orozco, Alicia, additional, Cantú-de-León, David, additional, and Prada, Diddier, additional

Published
2023
Full Text
View/download PDF

4. Psychometric properties of the Measurement of Current Status (MOCS) Scale in Mexican cancer patients.

Author

Espinoza Bello, Marcos, Galindo Vázquez, Oscar, Penedo, Frank J., Jiménez Ríos, Miguel Ángel, Ortega Andeane, Patricia, Scavuzzo, Anna, García Méndez, Mirna, and Meneses-García, Abelardo

Subjects
PSYCHOTHERAPY, PATIENTS' attitudes, PSYCHOMETRICS, BEHAVIORAL medicine, IMPACT of Event Scale, PSYCHO-oncology, PROSTATE cancer, THYROID cancer
Published
2023
Full Text
View/download PDF

5. Genomic Profile in a Non-Seminoma Testicular Germ-Cell Tumor Cohort Reveals a Potential Biomarker of Sensitivity to Platinum-Based Therapy

Author

González-Barrios, Rodrigo, Alcaraz, Nicolás, Montalvo-Casimiro, Michel, Cervera, Alejandra, Arriaga-Canon, Cristian, Munguia-Garza, Paulina, Hinojosa-Ugarte, Diego, Sobrevilla-Moreno, Nora, Torres-Arciga, Karla, Mendoza-Perez, Julia, Diaz-Chavez, José, Cortes-González, Carlo Cesar, Castro-Hernández, Clementina, Martínez-Cedillo, Jorge, Scavuzzo, Ana, Pérez-Montiel, Delia, Jiménez-Ríos, Miguel A., Herrera, Luis A., González-Barrios, Rodrigo, Alcaraz, Nicolás, Montalvo-Casimiro, Michel, Cervera, Alejandra, Arriaga-Canon, Cristian, Munguia-Garza, Paulina, Hinojosa-Ugarte, Diego, Sobrevilla-Moreno, Nora, Torres-Arciga, Karla, Mendoza-Perez, Julia, Diaz-Chavez, José, Cortes-González, Carlo Cesar, Castro-Hernández, Clementina, Martínez-Cedillo, Jorge, Scavuzzo, Ana, Pérez-Montiel, Delia, Jiménez-Ríos, Miguel A., and Herrera, Luis A.

Abstract

Despite having a favorable response to platinum-based chemotherapies, ~15% of Testicular Germ-Cell Tumor (TGCT) patients are platinum-resistant. Mortality rates among Latin American countries have remained constant over time, which makes the study of this population of particular interest. To gain insight into this phenomenon, we conducted whole-exome sequencing, microarraybased comparative genomic hybridization, and copy number analysis of 32 tumors from a Mexican cohort, of which 18 were platinum-sensitive and 14 were platinum-resistant. We incorporated analyses of mutational burden, driver mutations, and SNV and CNV signatures. DNA breakpoints in genes were also investigated and might represent an interesting research opportunity. We observed that sensitivity to chemotherapy does not seem to be explained by any of the mutations detected. Instead, we uncovered CNVs, particularly amplifications on segment 2q11.1 as a novel variant with chemosensitivity biomarker potential. Our data shed light into understanding platinum resistance in a Latin-origin population.

Published
2022

7. Genomic Profile in a Non-Seminoma Testicular Germ-Cell Tumor Cohort Reveals a Potential Biomarker of Sensitivity to Platinum-Based Therapy

Author

González-Barrios, Rodrigo, primary, Alcaraz, Nicolás, additional, Montalvo-Casimiro, Michel, additional, Cervera, Alejandra, additional, Arriaga-Canon, Cristian, additional, Munguia-Garza, Paulina, additional, Hinojosa-Ugarte, Diego, additional, Sobrevilla-Moreno, Nora, additional, Torres-Arciga, Karla, additional, Mendoza-Perez, Julia, additional, Diaz-Chavez, José, additional, Cortes-González, Carlo Cesar, additional, Castro-Hernández, Clementina, additional, Martínez-Cedillo, Jorge, additional, Scavuzzo, Ana, additional, Pérez-Montiel, Delia, additional, Jiménez-Ríos, Miguel A., additional, and Herrera, Luis A., additional

Published
2022
Full Text
View/download PDF

14. The PXR rs7643645 Polymorphism Is Associated with the Risk of Higher Prostate-Specific Antigen Levels in Prostate Cancer Patients

Author

Reyes-Hernández, Octavio D., primary, Vega, Libia, additional, Jiménez-Ríos, Miguel A., additional, Martínez-Cervera, Pedro F., additional, Lugo-García, Juan A., additional, Hernández-Cadena, Leticia, additional, Ostrosky-Wegman, Patricia, additional, Orozco, Lorena, additional, and Elizondo, Guillermo, additional

Published
2014
Full Text
View/download PDF

15. Oncological outcomes of retroperitoneal node dissection for residual masses after chemotherapy in germ cell tumor. Retrospective analysis of 15 years.

Author

Piñón-Solis EO, Jiménez-Ríos MA, Scavuzzo A, and Martínez-Cervera PF

Subjects
Adult, Dissection, Humans, Lymph Node Excision, Male, Retroperitoneal Space, Retrospective Studies, Treatment Outcome, Neoplasms, Germ Cell and Embryonal drug therapy, Neoplasms, Germ Cell and Embryonal surgery, Testicular Neoplasms drug therapy, Testicular Neoplasms surgery
Abstract

Objective: To report experience in a hospital in Mexico regarding oncological results in overall survival (OS) and specific cancer survival (SCS), the presence of recurrence in the management of residual masses after chemotherapy with lymphadenectomy retroperitoneal for 15 years., Method: Between 2004 and 2019, a retrospective study was carried out in a single centre with patients with a germ cell tumor diagnosis who have received first or second line of chemotherapy and who present retroperitoneal residual mass were included have performed RPLND. Sociodemographic characteristics were analyzed, overall and histological survival., Results: 346 patients had inclusion criteria, mean age was 27.6 years, the most affected testis was the left, the most frequent testicular histology was mixed germline. The most frequent retroperitoneal location was paraortic, the most frequent type of RPLND was standard, the most frequent histology was necrosis. Recurrence occurred in 24.2%, mean of 17.1 months, when analyzing individual factors, the most significant was the type of RPLND. The clinical stage, histology of the retroperitoneal tumor and type of RPLND influence mortality. Global follow up of 141 months, OS was 85.5% and SCS was 86.1%, mean of 139.9 months and 141 months respectively., Conclusions: RPLND is effective in survival and recurrence in advanced disease in patients who present postchemotherapy retroperitoneal tumor and although there is a clear benefit in the resection of retroperitoneal tumors in teratoma, there are conditioning factors that must be analyzed individually.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results